Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/24/25
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 ResultsZacks Investment Research • 01/16/25
Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 01/14/25
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate UpdatesBusiness Wire • 01/13/25
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/25
Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?Zacks Investment Research • 12/12/24
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver MeetingBusiness Wire • 11/14/24
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/12/24
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 11/12/24
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024Business Wire • 11/04/24
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/31/24
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual MeetingBusiness Wire • 10/31/24
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary CholangitisBusiness Wire • 10/10/24
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/06/24
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 08/07/24
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024Business Wire • 07/31/24
Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?Zacks Investment Research • 07/29/24